LXRX News and Press, Lexicon Pharmaceuticals Inc. From 06/29/22

Gainers: Adagene ( ADAG ) +20.3 % . Qorvo ( QRVO ) +11.5% . Lexicon Pharmaceuticals ( LXRX ) +9.8% . Avadel Pharmaceuticals ( AVDL ) +9.0% . The RealReal ( REAL ) +7.3% . Losers: HyperFeed Technologies ( HYPR ) ...

Lexicon Pharmaceuticals ( NASDAQ: LXRX ) is up 9% in after-hours trading after releasing phase 2 top-line data for LX9211, its candidate for diabetic neuropathy. The drug met its primary endpoint, statistically significant reduction in average daily pain score at ...

Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m. Eastern Time June 30, 2022 THE WOODLANDS, Texas, June 29, 2022 (GLOBE ...

Athira Pharma ATHA -65% as lead asset fails in Alzheimer’s trial. WISeKey International WKEY -43% on reports that it expects revenue growth in semiconductors IoT segment despite shortages in manufacturing. Micro Focus International (MFGP) -18%. Tabula Rasa HealthCar...

THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET. A...

Lexicon has not been lucky with the FDA. However, there are reasons, discussed below, which make me see a special situation here. It may not be a bad idea to take the plunge. For further details see: Lexicon: Beaten Down Stock, High Risk-Reward Situation Ahead

Lexicon Pharmaceuticals (NASDAQ:LXRX) said it resubmitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of sotagliflozin to treat heart failure. The company said the FDA has a 60-day filing review period to determine if the NDA is complete a...

THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the tr...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have been through an extended lean patch, making them ideal candidates for a strong rebound. Verrica ( VRCA ): Approval of its viral skin disease treatment could transform the company into a commerci...

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2022 Results Conference Call May 05, 2022 08:00 AM ET Company Participants Charles Schultz - Investor Relations Lonnel Coats - President and Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Senior Vice Presi...